Autoantibodies have already proven to be useful in T1D research, autoantibodies against native insulin were associated with differential outcome of immunotherapy [60], and pancreas transplant recipients with autoantibodies to native GAD65 were better served with thymoglobulin induction therapy than daclizumab to reduce their risk of rejection episodes [61]. This evidence concerns the gene GAD2 and type 1 diabetes mellitus.